FDA Grants Priority Review for BIZENGRI Supplement by Merus N.V.
The FDA has granted priority review for the supplemental application of BIZENGRI (ZENOCUTUZUMAB-ZBCO) submitted by Merus N.V.
Published: July 14, 2026
Updated: July 14, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / BiTE
Company: BiTE
Asset: BIZENGRI
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
BiTE
Asset
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's grant of priority review for BIZENGRI represents a significant regulatory milestone that could accelerate its market entry. This development is crucial for Merus N.V. as it enhances their competitive positioning in the oncology sector.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's final decision timeline and any upcoming advisory committee meetings related to BIZENGRI.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.